Lilly(Eli) & Co
NYSE:LLY
Other Pre-Announcement
Lilly Reports Fourth-Quarter 2022 Financial Results
Published: 02/02/2023 12:01 GMT
Lilly(Eli) & Co (LLY) - Lilly Reports Fourth-quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-term Outlook.
Eli Lilly - 2023 EPS Guidance Updated to Be in Range of $7.90 to $8.10 on a Reported Basis and $8.35 to $8.55 on a Non-GAAP Basis.
Eli Lilly - for Q4 2022, Worldwide Trulicity Revenue Was $1.94 Billion, an Increase of 3% Compared With Q4 2021.
Eli Lilly - for Q4 2022, Worldwide Verzenio Revenue Increased 100% Compared With Q4 2021 to $808.0 Million.
Eli Lilly - for Q4 2022, Worldwide Taltz Revenue Increased 9% Compared With Q4 2021 to $707.8 Million.
Eli Lilly - for Q4 2022, Worldwide Mounjaro Revenue Was $279.2 Million.
U.S. Revenue Was $256.7 Million.
Q4 Earnings per Share View $1.78, Revenue View $7.33 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2023 Earnings per Share View $8.28, Revenue View $30.55 Billion -- Refinitiv Ibes Data (analyst estimates).
Eli Lilly - 2023 EPS Guidance Updated to Be in Range of $7.90 to $8.10 on a Reported Basis and $8.35 to $8.55 on a Non-GAAP Basis.
Eli Lilly - for Q4 2022, Worldwide Trulicity Revenue Was $1.94 Billion, an Increase of 3% Compared With Q4 2021.
Eli Lilly - for Q4 2022, Worldwide Verzenio Revenue Increased 100% Compared With Q4 2021 to $808.0 Million.
Eli Lilly - for Q4 2022, Worldwide Taltz Revenue Increased 9% Compared With Q4 2021 to $707.8 Million.
Eli Lilly - for Q4 2022, Worldwide Mounjaro Revenue Was $279.2 Million.
U.S. Revenue Was $256.7 Million.
Q4 Earnings per Share View $1.78, Revenue View $7.33 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2023 Earnings per Share View $8.28, Revenue View $30.55 Billion -- Refinitiv Ibes Data (analyst estimates).